Trial reportMicrobiologyOpen2026
Susceptibility-Guided Versus Empirical Therapy for Helicobacter pylori Infection in a High Resistance Setting: A Randomised Controlled Trial.
Trial report in MicrobiologyOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05549115 (Susceptibility-Guided Sequential Therapy Versus Empirical Therapy for Helicobacter Pylori Infection), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Susceptibility-Guided Sequential Therapy Versus Empirical Therapy for Helicobacter Pylori Infection: a Randomised Controlled Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clarithromycin resistance is a major determinant of treatment failure, and the benefits of susceptibility-guided therapy in high-resistance settings remains incompletely understood. To evaluate the clinical effectiveness of the susceptibility-guided compared with the empirical therapy in treatment-naïve H. pylori infection in a high resistance setting. In this single-centre, randomised, superiority trial, 500 treatment-naïve adults were allocated (1:1) to susceptibility-guided sequential therapy (SGT) or empirical clarithromycin -containing quadruple therapy (ET). Clarithromycin and levofloxacin antimicrobial resistance were determined using PCR. The primary endpoint was first-line eradication in the intention-to-treat (ITT) population. Sensitivity analyses were performed using complete-case and multiple imputation approaches. Among the 494 analysed participants (244 SGT, 250 ET), resistance to clarithromycin and levofloxacin was 69.3% and 51.6%, respectively. In the ITT analysis, first-line eradication was achieved in 59.8% of participants in the SGT group and 62.8% in the ET group [absolute risk difference -3.0%; odds ratio (OR) = 0.882, 95% confidence interval (CI, 0.614-1.268), p = 0.499]. Per-protocol eradication rates were 84.4% and 89.7%, respectively [absolute risk difference -5.3%; OR = 0.620, 95% CI (0.328-1.173), p = 0.139]. Notably, despite a clarithromycin resistance rate approaching 70%, empirical clarithromycin-containing quadruple therapy achieved a high per-protocol eradication rate. Sensitivity analyses yielded consistent results. In a high resistance region, PCR-based susceptibility-guided sequential therapy did not demonstrate superiority over empirical treatment. However, empirical clarithromycin -containing quadruple therapy maintained satisfactory efficacy. Overall, these findings have implications for treatment strategy selection in high-resistance microbiological settings. Trial Registration: ClinicalTrials. gov Identifier: NCT05549115.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.